Sally Baird, NP
Family · Hudson, NCNPI 1710153515
Payments from drug & device makers
Across 146 payments — averaging $19.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$498
- Lilly USA, LLC$418
- AbbVie$357
- GSK$316
- Pfizer$258
- AstraZeneca$199
- plus $757 from 18 others
What the payments were for
- Food & beverage$2,802100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 27 | $498 |
| Lilly USA, LLC | 19 | $418 |
| AbbVie | 22 | $357 |
| GSK | 15 | $316 |
| Pfizer | 13 | $258 |
| AstraZeneca | 12 | $199 |
| Bayer | 3 | $137 |
| Boehringer Ingelheim | 5 | $85 |
| Abbott | 3 | $74 |
| Sanofi-aventis U.S. LLC | 4 | $71 |
| Dexcom, Inc. | 3 | $70 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $58 |
| Mannkind Corporation | 2 | $32 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Mylan Specialty L.p. | 2 | $27 |
| Verona Pharma, Inc. | 1 | $23 |
| Novartis | 1 | $21 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Exact Sciences | 1 | $19 |
| Viatris Specialty LLC | 1 | $19 |
| Johnson & Johnson | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,802 in reported general payments places this provider in the 85th percentile of 4,522 family providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 121 | $137,786 |
| JardianceEmpagliflozin | 107 | $112,529 |
| MounjaroTirzepatide | 41 | $43,432 |
| RybelsusSemaglutide | 41 | $39,664 |
| EliquisApixaban | 42 | $29,751 |
| XareltoRivaroxaban | 25 | $23,504 |
| Tresiba Flextouch U-200Insulin Degludec | 26 | $23,258 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $22,457 |
| TrulicityDulaglutide | 21 | $22,034 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $17,376 |
| Tresiba Flextouch U-100Insulin Degludec | 26 | $15,531 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $10,556 |
| FarxigaDapagliflozin Propanediol | 12 | $10,175 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 14 | $10,096 |
| SymbicortBudesonide/Formoterol Fumarate | 28 | $8,509 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $498 | $177,450162 claims |
| Boehringer IngelheimJardiance | $85 | $112,529107 claims |
| Lilly USA, LLCMounjaro, Trulicity | $418 | $65,46662 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $199 | $36,05956 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $316 | $33,01356 claims |
| PfizerEliquis | $258 | $29,75142 claims |
| Johnson & JohnsonXarelto | $16 | $23,50425 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,522 family providers in North Carolina.
Other family in Hudson
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
- Debra ScottCharlotte$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.